inflammatory bowel disease ibd epidemiology forecast
- Ulcerative Colitis is classified as mild, moderate, and severe. It has been observed that up to 50% of patients have a mild disease at the time of diagnosis, and up to 20% of patients have a severe disease at the time of diagnosis.
- In 2025, there were approximately 1 million mild cases of IBD in the US, while the majority of cases, around 2 million were classified as moderate to severe, highlighting the significant severity and progression of the disease.
- Among EU4 and the UK, Germany (~35) had the highest prevalent cases of IBD followed by UK, and Spain (~10%) accounted for the lowest cases in 2025.
- Companion diagnostics, biomarker-driven treatment selection, and precision medicine approaches are emerging as key areas of focus in IBD management, with ongoing research aiming to optimize therapy sequencing and improve individualized treatment outcomes.
Inflammatory Bowel Disease (IBD) Epidemiology Forecast in the US
- 2025 Prevalent Cases of IBD: ~5.5 million
- IBD Growth Rate (2026–2036): ~5% CAGR
DelveInsight's ‘Inflammatory Bowel Disease (IBD) – Epidemiology Forecast – 2036’ report delivers an in-depth understanding of the IBD, historical and forecasted epidemiology, in the United States, EU4 (Germany, Spain, Italy, and France) and the United Kingdom, and Japan.
|
Study Period |
2022–2036 |
|
Historical Year |
2022–2025 |
|
Forecast Period |
2026–2036 |
|
Base Year |
2026 |
|
Geographies Covered |
|
|
Inflammatory Bowel Disease (IBD) Epidemiology CAGR (Forecast period) |
~5% (2026–2036) |
|
Inflammatory Bowel Disease (IBD) Epidemiology Segmentation Analysis |
Patient Burden Assessment
|
Inflammatory Bowel Disease (IBD) Understanding and Diagnosis Algorithm
Inflammatory Bowel Disease (IBD) Overview
IBD is a group of chronic, relapsing inflammatory disorders of the gastrointestinal tract, primarily comprising Crohn’s disease and ulcerative colitis. Crohn’s disease can affect any part of the gastrointestinal tract and is characterized by transmural inflammation, whereas ulcerative colitis is limited to the colon and rectum with inflammation confined mainly to the mucosal layer. The exact etiology of IBD remains unclear. However, genetic susceptibility, immune dysregulation, environmental factors, gut microbiota alterations, and lifestyle changes are considered major contributors to disease development. The prevalence of IBD has increased significantly across the 7MM, particularly in developed countries, creating a substantial clinical and economic burden.
Further details are provided in the report.
Inflammatory Bowel Disease (IBD) Diagnosis
The diagnosis of IBD is based on a combination of clinical evaluation, laboratory testing, endoscopy, histopathology, and imaging studies. Common symptoms include abdominal pain, diarrhea, rectal bleeding, weight loss, fatigue, and urgency. Colonoscopy with biopsy remains the gold standard for diagnosis and disease assessment, while additional tools such as fecal calprotectin testing, C-reactive protein (CRP) measurement, CT enterography, MRI, and capsule endoscopy help evaluate disease activity and complications. Early and accurate diagnosis is important to prevent disease progression, intestinal damage, and complications such as strictures, fistulas, and colorectal cancer.
Further details are provided in the report.
Inflammatory Bowel Disease (IBD) Epidemiology
Key Findings from Inflammatory Bowel Disease (IBD) Epidemiological Analysis and Forecast
- In 2025, the total diagnosed prevalent cases of IBD in the US were found to be ~2,800,000 which was highest among the 7MM.
- Among the total diagnosed prevalent cases of IBD majority of cases were accounted by ulcerative colitis accounting ~57% of total cases of IBD cases in the US in 2025.
- In 2025, there were more than one million cases falling in the age group of 18-44 years which was highest among other age group for IBD in the US followed by 45-64 years.
- Ulcerative colitis cases based on severity of disease were more in moderate to severe (~60%) than in mild in EU4 and the UK in 2025.
- Crohn’s disease is typically more severe than ulcerative colitis but is slightly less common. The disease can occur at any age, but Crohn’s disease is most often diagnosed in adolescents and adults between 20 and 30 years of age.
Scope of the Report
- The report covers a segment of a descriptive overview of IBD, explaining their causes, signs and symptoms, and pathogenesis.
- Comprehensive insight has been provided into the epidemiology segments and forecasts, the future growth potential of the diagnosis rate, and disease progression.
Report Insights
Inflammatory Bowel Disease (IBD) Patient Population Forecast
Report Key Strengths
- Epidemiology‑based (Epi‑based) Bottom‑up Forecasting
- 11-year Forecast
- Patient Burden Trends (by Geography)
FAQs
- What are the disease risks, burdens, and unmet needs of IBD? What will be the growth opportunities across the 7MM concerning the patient population with IBD?
- What is the historical and forecasted IBD patient pool in the US, EU4 (Germany, France, Italy, and Spain), the UK, and Japan?
Reasons to Buy
- Insights on patient burden/disease prevalence, evolution in diagnosis, and factors contributing to the change in the epidemiology of the disease during the forecast years.
- To understand key opinion leaders’ perspectives around the diagnostic challenges to overcome barriers in the future.
- Detailed insights on various factors hampering disease diagnosis and other existing diagnostic challenges.
-diagnostic-market.png&w=256&q=75)
